Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arnold & Porter beefs up pharmaceutical group

Executive Summary

Arnold & Porter adds Daniel Kracov as partner and co-head of the pharmaceutical and medical device group and Kathleen Means as the group's non-lawyer senior policy advisor. Kracov and Means both hail from Patton Boggs; Kracov was the leader of Patton Boggs' FDA group. Means is a former Senate Finance Committee health advisor and House Ways & Means Committee staffer. She also worked in the senior executive service at the Centers for Medicare & Medicaid Services (1"The Pink Sheet" June 14, 2004, p. 25)...

You may also be interested in...

HHS Rx Price Negotiations Could Gain Bipartisan Support, Consultant Says

Congress will move to strike down the Medicare Rx law's "non-interference" provision in the next two years, former Senate Finance Committee health advisor Kathleen Means said at the Biotechnology Industry Organization's annual conference in San Francisco June 9

India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

Products Distributed In Bulk Could Pump Up Already Large OTC Sanitizer Problem In US

“Regardless of whether the adulterated products are sold on store shelves, online to consumers, or in bulk format to businesses and other organizations, FDA’s priority is safety," says American Cleaning Institute VP James Kim.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts